FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphoma.

FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphoma.
复制标题

FLU-ID(氟达拉滨和伊达比星)方案作为预先治疗的低度非霍奇金淋巴瘤的挽救疗法。

DOI:
--
复制
发表时间:
1996
期刊:
影响因子:
10.1
通讯作者:
S. Tura
S. Tura
中科院分区:
医学1区
文献类型:
--
作者:
P. Zinzani;M. Bendandi;F. Gherlinzoni;E. Merla;A. Gozzetti;S. Tura

文献摘要

参考文献

被引文献

相似文献

氟达拉滨(Fludarabine,FLU)是一种新的抗代谢化疗药物,对淋巴组织增生性疾病,特别是低度非霍奇金淋巴瘤(LG-NHL)具有良好的治疗作用。最近,一些报告描述了在多化疗方案中使用FLU的有趣结果。为了评估FLU与其他抗肿瘤药物的联合治疗,我们使用FLU和伊达比妥联合治疗,称为FLU-ID方案,治疗10例复发性LG-NHL患者。FLU-ID方案如下:第1 - 3天静脉注射FLU 25 mg/sqm,第1天静脉注射艾达鲁肽12 mg/sqm。10例患者中,2例(20%)达到完全缓解(CR),5例(50%)部分缓解,其余3例未显示治疗获益。2例CR患者分别在6个月和8个月后仍处于缓解状态。所有患者的中位总生存期为8个月。观察到的主要毒性反应为中性粒细胞减少症(40%)和感染和/或发热事件(15%);未发生因药物副作用导致的死亡。这些结果表明FLU-ID方案在诱导复发性LG-NHL的良好缓解率和中度副作用方面的功效。
Fludarabine (FLU) is a new antimetabolite chemotherapeutic agent with promising activity in lymphoproliferative disorders and, in particular, in low-grade non-Hodgkin's lymphoma (LG-NHL). Recently, a few reports have described interesting results using FLU in polychemotherapy regimens. In order to evaluate FLU in combination with other antineoplastic agents, we used a combination of FLU and idarubicin, called the FLU-ID regimen, to treat 10 patients with recurrent LG-NHL. The FLU-ID regimen was as follows: FLU 25 mg/sqm i.v. on days 1 to 3 and idarubicin 12 mg/sqm i.v. on day 1. Of the 10 patients, 2 (20%) achieved complete response (CR), 5 (50%) partial response, and the remaining 3 showed no benefit from the treatment. The 2 CR patients are still in remission after 6 and 8 months, respectively. The median duration of overall survival of all patients was 8 months. The major toxic effects observed were neutropenia (40%) and infections and/or febrile episodes (15%); no fatalities due to drug side effects occurred. These results indicate the efficacy of the FLU-ID regimen in inducing a good remission rate with moderate side effects in recurrent LG-NHL.
DOI: --
发表时间: 1971-11
期刊: Cancer research
影响因子: 11.2
作者:
P. Carbone;H. Kaplan;K. Musshoff;D. Smithers;M. Tubiana
通讯作者: P. Carbone;H. Kaplan;K. Musshoff;D. Smithers;M. Tubiana